Press releaseBusiness Wire
Janux Therapeutics
JANX · NASDAQ
$17.20+$0.46 (+2.75%)TodayMarket closed ·
Prev close $16.74
Latest news
- Press releaseBusiness Wire
Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
- Press releaseBusiness Wire
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
- NewsVandana Singh
Janux Therapeutics Halts Early Stage Cancer Program In 'Prudent' Move
- Press releaseBusiness Wire
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development
- Press releaseBusiness Wire
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
- News
Janux Therapeutics Nominates Development Candidate Under Collaboration, License Agreement With Bristol Myers Squibb
- Press releaseBusiness Wire
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment
- Press releaseBusiness Wire
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
- Press releaseBusiness Wire
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011
- Press releaseBusiness Wire
Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer
- NewsVandana Singh
Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million
- Press releaseBusiness Wire
Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors
- Press releaseBusiness Wire
Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study
- NewsAvi Kapoor
Gold Down Over 1%; Signet Shares Fall After Q3 Results
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- NewsVandana Singh
Janux Therapeutics Stock Hits 52-Week Low After Trial Update
- NewsAvi Kapoor
Nasdaq Surges 200 Points; United Natural Foods Posts Upbeat Earnings
- NewsAvi Kapoor
Applied Materials To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Tuesday
- NewsAvi Kapoor
Signet Jewelers, Janux Therapeutics, BW LPG And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
- NewsAvi Kapoor
Why MongoDB Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket
- Press releaseBusiness Wire
Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC
- News
10 Health Care Stocks With Whale Alerts In Today's Session
- Press releaseBusiness Wire
Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC
- Press releaseBusiness Wire
Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
- Press releaseBusiness Wire
Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
- Press releaseBusiness Wire
Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck
- Press releaseBusiness Wire
Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day
- Press releaseBusiness Wire
Janux Therapeutics to Host Virtual R&D Day on July 24, 2025
- News
10 Health Care Stocks Whale Activity In Today's Session
- Press releaseBusiness Wire
Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer
- Press releaseBusiness Wire
Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
- Press releaseBusiness Wire
Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates
- Press releaseBusiness Wire
Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
- Press releaseBusiness Wire
Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer
- News
Navigating 10 Analyst Ratings For Janux Therapeutics
- NewsAvi Kapoor
Why Credo Technology Group Shares Are Trading Higher By 40%; Here Are 20 Stocks Moving Premarket
- News
Evaluating Janux Therapeutics: Insights From 6 Financial Analysts
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.